Boston Scientific Becomes Only Company With Two Drug-Eluting Stent Platforms With European Approval of Everolimus-Eluting PROMUS(TM) Stent System

Boston Scientific Becomes Only Company With Two Drug-Eluting Stent Platforms With European Approval of Everolimus-Eluting PROMUS(TM) Stent System

October 18, 2006

PROMUS stent to complement Company's market-leading TAXUS(TM) stent systems

    NATICK, Mass., Oct. 18 /Xinhua-PRNewswire/ -- Boston
Scientific Corporation (NYSE: BSX) announced today that the
PROMUS(TM) everolimus-eluting coronary stent system has
received CE Mark approval, making Boston Scientific the
only company to offer two distinct approved drug-eluting
stent (DES) platforms in the CE geographies. This approval
allows Boston Scientific to begin marketing the new DES in
the 25 countries of the European Union and will support
market registrations in other regulated countries in Asia,
Latin America and Eastern Europe.

    The PROMUS stent is a private-labeled Xience(TM) V
Everolimus-Eluting Coronary stent system manufactured by
Abbott and distributed by Boston Scientific.  It will
complement Boston Scientific's market-leading TAXUS(TM)
paclitaxel-eluting stent systems.  The Company expects to
launch the PROMUS stent in Europe in 2007.

    "We are very pleased that CE Mark approval has
been granted for this important expansion of our
drug-eluting stent portfolio," said Paul LaViolette,
Boston Scientific Chief Operating Officer. "Boston
Scientific is proud to be able to offer clinicians the
choice of a paclitaxel-eluting stent and an
everolimus-eluting stent from the same company, for the
first time. We look forward to complementing the proven
safety and efficacy of TAXUS with the tremendous potential
of PROMUS, further demonstrating the breadth and depth of
our DES pipeline as well as our overall leadership in
supplying innovative products to interventional
cardiologists." 

    Boston Scientific's TAXUS stent system has a record of
proven outcomes, including over three million TAXUS stents
implanted in patients worldwide and clinical follow-up on
nearly 3,500 patients out to four years in TAXUS
randomized, controlled clinical trials.  Positive results
for the Xience V stent were reported from the SPIRIT II
clinical trial at the recent World Congress of Cardiology
in Barcelona, Spain, showing that the Xience V stent met
its primary endpoint of non-inferiority to TAXUS as
measured by late loss at six months.  

    PROMUS and TAXUS are trademarks of Boston Scientific
Corporation or its affiliates. Xience V is a trademark of
Abbott.  The SPIRIT Clinical Program is sponsored by Abbott
Vascular. PROMUS is not approved for sale in the U.S.

    Boston Scientific is a worldwide developer,
manufacturer and marketer of medical devices whose products
are used in a broad range of interventional medical
specialties.  For more information, please visit:
http://www.bostonscientific.com .   

    This press release contains forward-looking statements.
 Boston Scientific wishes to caution the reader of this
press release that actual results may differ from those
discussed in the forward-looking statements and may be
adversely affected by, among other things, risks associated
with new product development and commercialization, clinical
trials, intellectual property, regulatory approvals,
competitive offerings, Boston Scientific's overall business
strategy, and other factors described in Boston Scientific's
filings with the Securities and Exchange Commission. 

    For more information, please contact:

     Geraldine Varoqui
     Boston Scientific PR Manager International
     Tel:   [phone]
     Email: [e-mail]

     Tracy Paul
     BSC press office
     Tel:   [phone]
     Email: [e-mail]

SOURCE  Boston Scientific Corporation